Biocon Limited — Q1 FY26
Biocon Group delivered a strong Q1 FY26 with consolidated operating revenue of INR 3,942 crore, up 15% YoY on a like-for-like basis.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
79%Questions answered1Evaded / deflected12Questions auditedContradictedNumbers vs filing
Evasive
High priority
Why did biosimilar gross margin decline 150 bps? Is growth from discounted tenders?
Asked by Damayanti Kerai, HSBC
Management avoided explaining the gross margin decline and instead highlighted EBITDA improvement.
did not address gross margin declineredirected to EBITDA margin improvement
Read the exchange
Question
When we look at the gross margin part, there is a decline of, say, 150 basis points or so. I just want to understand, specifically from biosimilars sale, whatever incremental sales you are recording, is that coming from more discounted tender channels, etc., and how should we look at the trend ahead?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
I think if you noted Kiran's commentary, the biosimilars biologics business has performed very strongly in the quarter. Not only has the revenue grown 18% year-on-year, there's also been an improvement in the EBITDA margin.
Answered
High priority
What is the debt level at parent and Biocon Biologics? Why did interest expense rise?
Asked by Damayanti Kerai, HSBC
Management provided specific debt figures and explained interest expense stability.
Read the exchange
Question
If you can say, like, what is the debt level at the parent as well as the Biocon Biologics Limited level? We have been talking about debt reduction for a couple of quarters. When we look at the interest expense for the quarter, I think it has gone up. Can you explain that as well?
Siddharth Mittal, CEO and Managing Director, Biocon
The debt, I think we have said that mainly it's at Biocon Biologics level. We have a net debt of roughly $1.1 billion in June at biosimilars level, approximately $100 million at generics level, and $120 million cash positive in research.
Answered
Medium priority
Will interest burden decrease from Q2?
Asked by Damayanti Kerai, HSBC
Management gave a clear timeline for interest reduction.
Read the exchange
Question
With some of these repayments on the way, should we assume interest burden to go down from Q2 itself, or will it happen in a more gradual manner?
Siddharth Mittal, CEO and Managing Director, Biocon
Q2 will definitely go down for Goldman Sachs, which had the 5% coupon on $180 million. That would go down, as I mentioned. Kotak and Edel will be more later part of this fiscal.
Answered
Medium priority
What is the regional revenue split for biosimilars?
Asked by Damayanti Kerai, HSBC
Management provided specific percentage splits for regions.
Read the exchange
Question
For biosimilars, can you give us the regional split, say, like U.S. and other market?
Kedar Upadhye, CFO, Biocon
This quarter, emerging market is about 23%. Advanced markets is about 77%. On a full-year basis, you should factor 75%-25%, Damayanti. Within 75% of the advanced markets, U.S., the North Am will be 40% +, and the balance will be rough.
Answered
High priority
What is the gross debt level on a consolidated basis?
Asked by Surya Patra, PhillipCapital
Management gave specific consolidated debt figure.
Read the exchange
Question
What is the gross debt level that we are having here right now on the consolidated level basis?
Siddharth Mittal, CEO and Managing Director, Biocon
It's that $1.1 billion. I'll repeat, Biocon Biologics has a net debt of $1.15 billion, $100 million debt in generics, $100 million cash in Syngene.
Partial answer
High priority
Is generics EBITDA impacted by one-time costs? Can you quantify?
Asked by Surya Patra, PhillipCapital
Management quantified the cost but did not clarify if it is one-time or recurring.
did not confirm if one-timesaid costs are ongoing
Read the exchange
Question
Whether there is no Revlimid sale in this quarter, that is one. Is there any one-time kind of spend because of the facility commercialization and all that, which may not be there in the subsequent quarter? If that is yes, can you quantify the one-time impact?
Siddharth Mittal, CEO and Managing Director, Biocon
The impact of all these facilities' operating costs are in the P&L, which is going to be on an ongoing basis. The impact is roughly INR 60 crore a quarter.
Answered
Medium priority
What is the minority interest in Biocon Biologics after fundraise?
Asked by Surya Patra, PhillipCapital
Management provided a specific percentage stake.
Read the exchange
Question
What is the minority interest then Biocon would be having enhanced in Biocon Biologics now?
Siddharth Mittal, CEO and Managing Director, Biocon
On a fully diluted basis, assuming all these, I mean, Goldman and Edel is paid out, we'll be up to 78% stake in Biocon Biologics.
Answered
Medium priority
Is there a compulsion for Biocon Biologics to list?
Asked by Surya Patra, PhillipCapital
Management clearly stated no compulsion to list.
Read the exchange
Question
Is it fair to believe that there is no compulsion on Biocon Biologics to go for a listing?
Siddharth Mittal, CEO and Managing Director, Biocon
No, there's no compulsion. I think we have said that IPO is a, I mean, the commitment to Viatris that we had was the best effort. We have time to give exit to investors, which is in a few years. There's no compulsion as such.
Partial answer
High priority
What is the status of ustekinumab launch and aspart dual brand pricing?
Asked by Surya Patra, PhillipCapital
Management gave qualitative update on ustekinumab but avoided specifics on revenue and aspart pricing.
did not quantify revenuedid not address pricing strategy for aspart
Read the exchange
Question
One is the ustekinumab, whether we have seen any kind of a ramp-up or any revenue contribution from that from the U.S. market from that. The second point was about the launch of aspart, when we would be having a dual brand from Civica as well as from our own. Whether the pricing would be similar or whether we will have the advantage of the limited competition as well as the interchangeability benefit or not, because Civica pricing is likely to be relatively lower.
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
It's been a very successful launch led by our U.S. team there. I think one of the key things to bring to your attention is that we've had very strong formulary coverage for this product.
Answered
High priority
Is there still runway to improve Stelara market share?
Asked by Neha Manpuria, Bank of America
Management confirmed further runway and provided context on payer transitions.
Read the exchange
Question
If I look at the IQVIA number, we've seen a very strong market share trend. This does not necessarily reflect all of the contracts as yet, right? We could continue to see this momentum build as we see new contracts coming in in July. Is there a fair bit of runway to improve market share still in Stelara?
Matt Erick, Chief Commercial Officer Advanced Markets, Biocon Biologics
As the products continue to transition the Stelara from the payers starting July 1, you're starting to see what Shreehas said, early uptake of ustek. These products will continue to see, we see one full basis point that has contributed to that increase in June.
Answered
High priority
How sticky is Stelara market share given competition?
Asked by Neha Manpuria, Bank of America
Management explained stickiness due to interchangeability and early adoption.
Read the exchange
Question
Given that this is a fairly competitive product, how should I think about the stickiness of the market share for Stelara? I'm just trying to understand, is there a risk that you could see the competition probably chip away on share come the next contract cycle?
Matt Erick, Chief Commercial Officer Advanced Markets, Biocon Biologics
Doctors are getting used to writing Yesintek. Remember, interchangeability is not to each biosimilar. It's only to the brand. As the patients and doctors get used to utilizing the Biocon Yesintek, it becomes very sticky.
Partial answer
High priority
Will oncology biosimilar pressure offset Stelara margin gains?
Asked by Neha Manpuria, Bank of America
Management defended oncology strength but did not address potential margin offset.
did not quantify margin impactavoided direct offset question
Read the exchange
Question
Given that we're seeing competition now come back into the market, some of the gains that we've seen earlier this year seem to be coming off. Given there is more competition expected in oncology biosimilars, should we expect that margins for BBL will probably be at these levels with whatever we gain in Stellara being offset by the onco biosimilars seeing pressure?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics
We believe that the oncology franchise for us in the U.S. has been very, very strong. In fact, we still have over a fourth of the market with the two biosimilars that we've launched, and it continues to be very, very profitable.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Biosimilar revenue grew 18% YoY | 18% | 15% | Overstated vs filing |
| Normalized biosimilar EBITDA margin 24% | 24% | 25% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.